NEW YORK (GenomeWeb News) – Luminex said after the close of the market on Monday that revenues for its fourth quarter increased 16 percent year over year on the strength of its assays and related products as well as consumables sales.

Total revenues for the three months ended Dec. 31, 2012 were $55.5 million, up from $47.9 million in the year-ago period, and beat the consensus Wall Street estimate of $54.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.